Using an EHR-linked body-composition digital phenotyping pipeline with LLM-based extraction, we performed a large-scale longitudinal analysis of 670,422 first-episode GLP-1RA users, including 456,742 treated with semaglutide and 213,680 treated with tirzepatide
Semaglutide is a transformative obesity medication with Phase 3 data from tens of thousands of participants, FDA approval, proven cardiovascular benefit, and years of real-world use at scale
antioxidants: ascorbyle palmitate, tocopherol
Get 15% off with Peptides Kingdom promo code Visit peptideskingdom.com today to view the newest specials
Through weight reduction, GLP-1 medications can reduce or eliminate sleep apnea and lower blood pressure